Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation

Systematic review and meta-analysis of 10 real-world observational studies including patients with not valvular atrial fibrillation NVAF on apixaban and rivaroxaban was done to compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke. Surprisingly, apixaban treatment showed significantly lower hazard of 0.8 or 20% Risk reduction in stroke/systemic embolism compared to rivaroxaban. Also, meta-analysis for a major bleeding episode was significantly lower with 38% RR with apixaban compared with rivaroxaban The risk of Gastrointestinal bleeding was 43% lower in Apixaban compared to Rivaroxaban. In conclusion, this study suggests that CHA2DS2-VASc and HAS-BLED scores might be an important factor when selecting oral anticoagulants. Apixaban is associated with lower rates of both major bleeding and gastrointestinal bleeding than rivaroxaban, with no loss of efficacy. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.